RemeGen
PublicRemeGen is now publicly traded
The data on this page reflects RemeGen's private-market history up to the point it went public, including its funding rounds, valuation, and investors.
Went Public
Nov 9, 2020
Last Round
Follow-on Offering
Mar 31, 2022
Total Funding Raised
$1.03B
Company Overview
RemeGen is a biopharmaceutical company that focuses on the discovery, development, and commercialization of innovative biologic drugs for the treatment of autoimmune, oncology, and ophthalmic diseases.
Sector
Healthcare
AI Layer
Application
Keywords
RemeGen Comparables
Compare RemeGen with similar companies based on industry and business-model similarity.
No public comparables are available for RemeGen. Request access to learn about comparables coverage.
Request accessRemeGen Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Follow-on Offering | Mar 31, 2022 | ||||
| IPO | Nov 9, 2020 | ||||
| Private Equity | Mar 16, 2020 |
RemeGen Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Loyal Valley Capital | Private Equity |
| Lake Bleu Capital | IPO, Private Equity |
| Huatai International | IPO |
| Hillhouse Capital Group | IPO |
| OrbiMed | Private Equity, IPO |
| Morgan Stanley | IPO |
| Janchor Partners | Private Equity |
RemeGen Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request access